scholarly journals Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of early prostate cancer among men who underwent Robotic transperineal prostate biopsy

2020 ◽  
Author(s):  
Du Jingzeng ◽  
Ee Jean Lim ◽  
Hong Hong Hong Huang ◽  
Kam On Weber Kam On Lau
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Predictive Value ◽  
Gleason Grade ◽  
Early Prostate Cancer ◽  
Transperineal Prostate Biopsy ◽  
Cancer Group ◽  
Significant Difference ◽  
Benign Histology ◽  
Benign Group

Abstract Background NLR is known to have prognostic value for metastatic prostate cancer (PCa). However for early PCa due to lack of systemic response; the role of NLR is not conclusive. In this study we aim to evaluate the predictive value of NLR for early clinical PCa in patients who underwent robotic transperineal prostate biopsy (RTPB). Methods Patients who underwent RTPB under general anesthesia (GA), at the Department of Urology, Singapore General Hospital between Sep 2006 and Feb 2016 were retrospectively reviewed. Exclusion criteria includes: 1. Patients with missing value of PSA NLR 2. Patients who underwent biopsy for non-diagnostic purposes. 3. Patients with chronic inflammation or high grade prostatic intraepithelial neoplasia. Patients who had more than one biopsies and only the last histology results were included in this study. NLR was calculated for all patients using Complete blood count that was done as pre-admission test before GA within 4 weeks before operation. NLR values were compared between PCa; clinical significant PCa and benign group. Patients were divided further into different groups according to PSA level for subgroup analysis. Results A total 652 patients who underwent RTPB for diagnostic purpose with valid pre-procedure PSA level were included in this study. There were total 409 (62.7%) benign histology and 243 (37.3%) PCa cases. Median NLR in the benign histology group and PCa group were 2.00 and 1.99. There was no statistically significant (P=0.29). In the subgroups analysis, there were also no significant difference of median NLR value in clinical significant cancer group (defined as Gleason 3 + 4 and above) when compared to benign group (NLR 2.00 vs. 2.01, P=0.41) as well as in prostate cancer group and benign group according to different pre-biopsy PSA levels (PSA < 4, 4-10, 10-20 and > 20 ug/L), respectively. (P>0.05). NLR is not a significant predictor for Gleason grade group and D’Amico risk stratification group. (P>0.05) Conclusion There were no statistical significant difference of NLR between benign and prostate cancer group as a whole or in the subgroup analyses for patients who underwent RTPB. NLR may have a limited role in predicting early prostate cancer.

scholarly journals Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of early prostate cancer among men who underwent Robotic transperineal prostate biopsy

2019 ◽  
Author(s):  
Du Jingzeng ◽  
Ee Jean Lim ◽  
Hong Hong Huang ◽  
Weber Kam On Lau
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Predictive Value ◽  
Full Blood Count ◽  
Diagnostic Purpose ◽  
Transperineal Prostate Biopsy ◽  
Cancer Group ◽  
Significant Difference ◽  
Benign Histology ◽  
Benign Group

Abstract Background： NLR is known to have prognostic value for metastatic prostate cancer. However for early-localized prostate cancer due to lack of systemic response; the role of NLR is not conclusive. In this study we aim to evaluate the predictive value of NLR for early clinical indolent prostate cancer in patients who underwent robotic transperineal prostate biopsy (RTPB). Methods: Patients who underwent RTPB under general anesthesia, at Urology Department, Singapore General Hospital between Sep 2006 and Feb 2016 were retrospectively reviewed. NLR was calculated for all patients using full blood count (FBC) that was done as pre-admission test before GA within 4 weeks before operation. And NLR values were compared between prostate cancer (PCa) and benign group. Results: A total 652 patients who underwent RTPB for diagnostic purpose with valid PSA level were included in this study. There were total 409 (62.7%) benign histology and 243 (37.3%) prostate cancer. There was no significant difference of median NLR between benign and prostate cancer group (2.00 vs. 1.99; P=0.29). In the subgroups analysis, there were also no significant difference of median NLR value in clinical significant cancer (defined as Gleason 3 + 4 and above) and benign histology group (NLR 2.00 vs. 2.01, P=0.41), as well as prostate cancer and benign group according to different pre-biopsy PSA levels: PSA (ug/l) < 4, 4-10,10-20 and > 20, respectively. (Median NLR 1.34 vs. 1.76; 1.97 vs. 1.97; 1.97 vs. 2.18; 2.18 vs. 1.98, P>0.05) Conclusion: There were no statistical significant difference of NLR between benign and prostate cancer group as a whole or in the subgroup analyses for patients who underwent robotic transperineal prostate biopsy. NLR may have a limited role in predicting early stage prostate cancer.

scholarly journals A retrospective comparison between transrectal and transperineal prostate biopsy in the detection of prostate cancer

2017 ◽  
Vol 89 (1) ◽  
pp. 55 ◽  
Author(s):  
Carmelo Agostino Di Franco ◽  
Hussein Jallous ◽  
Daniele Porru ◽  
Giovanni Luca Giliberto ◽  
Tiziano Cebrelli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Complication Rate ◽  
Late Complication ◽  
Fisher Exact Test ◽  
Cancer Rate ◽  
Transperineal Prostate Biopsy ◽  
Significant Difference ◽  
Prostate Diseases ◽  
Clinical Records

Background: The aim of this study was to analyze the differences between TRUSguided transrectal prostate biopsy (TR) and transperineal prostate biopsy (TP) in the diagnosis of prostate cancer. The two biopsy methods were evaluated in terms of diagnostic sensitivity and of early and late complications. Methods: This retrospective study was realized through the review of clinical records of 219 men that received a prostate biopsy between 2004 and 2014. The biopsy was performed because of elevated prostate-specific antigen (PSA), abnormal digital rectal examination findings (DRE), abnormal transrectal ultrasound (TRUS) findings and symptoms due to prostate diseases. The cohort study was subdivided in two groups: 108 patients received a transrectal biopsy between 2004 and 2006 and 111 received a transperineal biopsy between 2007 and 2014. In both groups, first biopsy was performed with 12 cores scheme whereas second or third biopsy were performed with 18 cores scheme; in this study we excluded patients who underwent to biopsies with different number cores to reduce the bias. Both groups were evaluated on the basis of age, total PSA, PSA ratio (F/T), DRE/TRUS findings, presence/absence of low urinary tracts symptoms (LUTS), presence/absence of benign prostatic hyperplasia (BPH), histologic findings of biopsy cores and immediate/postoperative complications. Then, it was evaluated the overall cancer detection rate and the stratified cancer rate on the basis of the previous reported parameters. Finally, we analyzed the early and late complication rate in both groups. U Mann-Whitney test was used to evaluate the quantitative variables and χ<sup>2</sup>-test or Fisher exact test for qualitative variables. p &lt; 0.05 was considered statistically significant. Results: 66 cancers were detected in 219 patients of the study; 29 cancers were detected in the TP group and 37 in the TR group. There were no statistically significant differences in the overall cancer rate detected in both groups (26.13% e 34.26% respectively; p = 0.190). However, TP biopsy detected more cancers at first biopsy than TR biopsy (89.7% vs 78.4% respectively; p = 0.021). Moreover, TP biopsy detected more cancers in those patients with low cancer suspect (PSA &lt; 4 ng/ml, F/T &gt; 15%, negative TRUS), instead TR biopsy had more sensitivity in detecting cancer in those patients with high cancer suspect (PSA &gt; 10 ng/ml, F/T &lt; 15%, TRUS with abnormal lesions). The presence of BPH did not influence sensitivity in both cases. There were no significant differences in the early complication rate whereas a statistically significant difference was observed in the late complication rate (4% vs 11% in TP and TR biopsy, respectively; p = 0.019). Conclusions: No statistically significant differences in sensitivity were observed between TP and TR biopsy, but TP biopsy detected more cancers at first time biopsy. Complications rate was lower in the TP group. Therefore, we conclude that the Urologist has the final choice in deciding the most appropriate biopsy technique, considering sensitivity and complications.

scholarly journals COMPARISON BETWEEN TRANSRECTAL ULTRASONOGRAPHY GUIDED TRANSRECTAL PROSTATE BIOPSY AND TRANSRECTAL ULTRASONOGRAPHY GUIDED TRANSPERINEAL PROSTATE BIOPSY

2019 ◽  
Vol 26 (2) ◽  
Author(s):  
Randa Halfian ◽  
Doddy M Soebadi ◽  
Fikri Rizaldi
Keyword(s):  
Prostate Cancer ◽  
Rectal Bleeding ◽  
Prostate Biopsy ◽  
Pain Perception ◽  
Prostate Tissue ◽  
Transrectal Ultrasonography ◽  
P Value ◽  
Transperineal Prostate Biopsy ◽  
Significant Difference ◽  
Transrectal Prostate Biopsy

Objective: Prostate cancer is the fourth most common malignancy in men. TRUS guided transperineal prostate biopsy and TRUS guided transrectal prostate biopsy are two main approach to take prostate tissue as diagnostic of prostate cancer. To compare prostate biopsy approach between TRUS guided transrectal and TRUS guided transperineal toward duration of examination, pain perception, and complications. Material & Method: This study was an experimental study with prospective approach. There were two groups, group one was performed TRUS guided transrectal prostate biopsy (TRB) and group two was performed TRUS guided transperineal prostate biopsy (TPB). Evaluation was based on the duration of examination, pain perception, and complication. Data was analyzed using independent T test for duration of examination and Mann-Whitney test for pain perception. Data was performed using SPSS 21.0 version. The statistical significant difference was consider if p value <0.05. Results: There were 20 samples in this study. There was a significant difference in the duration of examination, the average duration of TPB examination (17.40 ± 2.50) was longer than the duration of TRB examination (14.1 ± 2.77). There was no significant statistical difference between TPB group and TRB group in pain perception when USG probe into the anal (p=0.65), anesthesia process (p=0.28), prostate tissue sampling (p=1.00), and post biopsy (p=0.34). Rectal bleeding was found mostly in TRB group (40%) compared to TPB group (0%). Hematuria was experienced by three patients (30%) in TRB group and two patients (20%) in TPB group. Conclusion: TRB was more effective in duration of biopsy than TPB. The complications of rectal bleeding and hematuria were more in TRB group than TPB. The pain perception were the same between both groups. There were no fever, sepsis, hematospermia and vasovagal event in two groups.

scholarly journals Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Andrew Leone ◽  
Katherine Rotker ◽  
Christi Butler ◽  
Anthony Mega ◽  
Jianhong Li ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Prostate Biopsy ◽  
Repeat Biopsy ◽  
Gleason Grade ◽  
High Grade ◽  
Atypical Small Acinar Proliferation ◽  
Prostate Biopsies ◽  
Significant Difference ◽  
Initial Biopsy

Purpose. Atypical small acinar proliferation (ASAP) is diagnosed in 1-2% of prostate biopsies. 30–40% of patients with ASAP may be diagnosed with prostate cancer (PCa) on repeat biopsy. Our objective was to examine the association between ASAP and subsequent diagnosis of intermediate/high risk PCa.Materials and Methods. Ninety-six patients who underwent prostate biopsy from 2000 to 2013 and were diagnosed with ASAP were identified. Clinicopathologic features were analyzed. Comparison was made between those with subsequent PCa on repeat biopsy and those with benign repeat pathology.Results. 56/96 (58%) patients had a repeat biopsy. 22/56 (39%) were subsequently diagnosed with PCa. There was no significant difference in patients’ characteristics. Presence of HGPIN on initial biopsy was associated with a benign repeat biopsy (68% versus 23%). 17/22 (77%) had Gleason grade (GG) 3+3 disease and only 5/22 (23%) had GG 3+4 disease.Conclusions. 22/56 patients (39%) of patients who underwent a subsequent prostate biopsy following a diagnosis of ASAP were found to have PCa. 77% of these men were diagnosed with GG 3+3 PCa. Only 23% were found to have intermediate risk PCa and no high risk PCa was identified. Immediate repeat prostate biopsy in patients diagnosed with ASAP may be safely delayed. A multi-institutional cohort is being analyzed.

1497: Predictive Value of Proliferative Inflammatory Atrophy (PIA) for Prostate Cancer on Repeat Prostate Biopsy

2006 ◽  
Vol 175 (4S) ◽  
pp. 483-483
Author(s):  
Charlie Jung ◽  
Michael S. Cookson ◽  
Matthew J. Putzi ◽  
Sam S. Chang ◽  
Joseph A. Smith ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Predictive Value ◽  
Proliferative Inflammatory Atrophy

scholarly journals Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (14) ◽  
pp. 23322-23336 ◽  
Author(s):  
Jianxin Xue ◽  
Zhiqiang Qin ◽  
Hongzhou Cai ◽  
Chuanjie Zhang ◽  
Xiao Li ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Sequential Analysis ◽  
Meta Analysis ◽  
Trial Sequential Analysis ◽  
Transperineal Prostate Biopsy

Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy

2005 ◽  
Vol 96 (7) ◽  
pp. 999-1004 ◽  
Author(s):  
E. David Crawford ◽  
Shandra S. Wilson ◽  
Kathleen C. Torkko ◽  
Daisaku Hirano ◽  
J. Scott Stewart ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Clinical Staging ◽  
Transperineal Prostate Biopsy

scholarly journals Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Maudy C. W. Gayet ◽  
Anouk A. M. A. van der Aa ◽  
Harrie P. Beerlage ◽  
Bart Ph Schrier ◽  
Maaike Gielens ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Detection Rates ◽  
Prostate Biopsies ◽  
Significant Difference ◽  
Significant Pathology ◽  
Study Population ◽  
Clinically Significant ◽  
Control Study

Objective. To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men. Methods. An in-patient control study of 82 men undergoing SB and subsequent TB in case of positive prostate MRI between 2015 and 2017 in the Jeroen Bosch Hospital, the Netherlands. Results. Prostate cancer (PCa) was detected in 54.9% with 70.7% agreement between TB and SB. Significant PCa (Gleason score ≥7) was detected in 24.4%. The CDR with TB and SB was 35.4% and 48.8%, respectively (p=0.052). The CDR of significant prostate cancer with TB and SB was both 20.7%. Clinically significant pathology upgrading occurred in 7.3% by adding TB to SB and 22.0% by adding SB to TB. Conclusions. There is no statistically significant difference between CDRs of SB and TB. Both SB and TB miss significant PCas. Moreover, pathology upgrading occurred more often by adding SB to TB than vice versa. This indicates that the omission of SB in this study population might not be justified.

Sign in / Sign up

Export Citation Format

Share Document